Drug Development

Coley Pharmaceutical Group announces data from clinical study of ACTILON for hepatitis C

Published in Hepatitis Weekly, May 29th, 2006

Coley Pharmaceutical Group, Inc. (COLY) announced positive four- and twelve-week treatment data from the company's five-arm Phase Ib clinical study of ACTILON (CPG 10101) alone and in combinations with pegylated interferon and/or ribavirin, among treatment-refractory patients chronically infected with hepatitis C virus (HCV).

Results indicate that the combination of ACTILON plus pegylated interferon and ribavirin achieved greater rates of HCV RNA undetectability (defined as less than lower limit of detection of 50 IU/mL) and improved Rapid and Early Virological Responses (RVR and EVR, defined as a greater than 2 log reduction in plasma HCV RNA levels at four and twelve...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry